ESPR
Esperion Therapeutics Inc
3.20$
+0.0%
vs. previous close
Closing price · As of: Jul 15, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 74.5% | 72.5% | 87.1% | 73.4% | 99.4% | 98.7% | 97.9% | 86.2% | 99.5% | 97.7% | 98.3% | 99.3% | |
| 59.3% | 26.2% | 15.6% | 12.4% | 25.8% | 77.5% | 86.3% | 54.7% | 50.3% | 40.0% | 42.1% | 36.0% | |
| 59.3% | 26.2% | 15.6% | 12.4% | 25.8% | 93.6% | 86.3% | 68.0% | 67.3% | 40.0% | 42.1% | 36.0% | |
| – | – | – | – | – | – | 3.5% | 6.0% | 13.6% | 23.6% | 23.3% | 30.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | 4.6% | 9.0% | 14.2% | 31.9% | 27.5% | 22.6% | |
| 0.5% | 0.3% | 0.3% | 0.2% | 0.4% | 0.5% | 0.4% | 0.2% | 0.1% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| 6.8% | 2.8% | 6.8% | 11.9% | 44.8% | 90.7% | 127.2% | 151.6% | 230.6% | 321.1% | 213.1% | 164.8% | |
| 3.8% | 1.9% | 6.4% | 11.9% | 44.8% | 30.8% | 26.6% | 19.2% | 37.2% | 75.9% | 71.6% | 64.6% | |
| 0.4% | 0.5% | 0.7% | 0.4% | – | 0.2% | 0.7% | 3.7% | 10.3% | 17.7% | 30.5% | 19.7% | |
| 1.4% | 0.2% | 1.9% | 7.3% | 31.3% | 13.5% | 14.7% | 4.6% | 9.3% | 15.4% | 15.0% | 14.0% | |
| 3.0% | 0.9% | 0.4% | 0.0% | – | 59.4% | 50.8% | 67.7% | 104.8% | 127.1% | 69.1% | 53.5% | |
| 93.2% | 97.2% | 93.2% | 88.1% | -416.9% | 9.3% | -27.2% | -51.6% | -130.6% | -221.1% | -113.1% | -64.8% | |
| -72.9% | -52.2% | -93.5% | -142.6% | -416.9% | -324.2% | -237.5% | -289.9% | -540.5% | -752.8% | -465.7% | -348.5% | |
| 11.4% | 7.4% | 9.2% | 8.6% | 18.7% | 12.6% | 7.8% | 7.6% | 26.8% | 50.1% | 54.4% | 44.6% |
Data as of: July 15, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.